Lesinski Gregory B, Trefry John, Brasdovich Melanie, Kondadasula Sri Vidya, Sackey Korkor, Zimmerer Jason M, Chaudhury Abhik Ray, Yu Lianbo, Zhang Xiaoli, Crespin Tim R, Walker Michael J, Carson William E
Human Cancer Genetics Program, Department of Molecular Virology, Immunology and Medical Genetics, The Ohio State University, Columbus, Ohio 43210, USA.
Clin Cancer Res. 2007 Sep 1;13(17):5010-9. doi: 10.1158/1078-0432.CCR-06-3092.
IFN-alpha is administered to melanoma patients and its endogenous production is essential for immune-mediated tumor recognition. We hypothesized that a reduced capacity for signal transducer and activator of transcription (STAT) 1 activation allows melanoma cells to evade the direct actions of IFN-alpha.
Tyr(701)-phosphorylated STAT1 (P-STAT1) was measured by flow cytometry in IFN-alpha-stimulated human melanoma cell lines, melanoma cells derived from patient tumors, and peripheral blood mononuclear cells (PBMC). Expression of other Janus-activated kinase (Jak)-STAT intermediates (STAT1, STAT2, Jak1, tyrosine kinase 2, IFN-alpha receptor, STAT3, and STAT5) was evaluated by flow cytometry, immunoblot, or immunohistochemistry.
Significant variability in P-STAT1 was observed in human melanoma cell lines following IFN-alpha treatment (P < 0.05) and IFN-alpha-induced P-STAT1 correlated with the antiproliferative effects of IFN-alpha (P = 0.042). Reduced formation of P-STAT1 was not explained by loss of Jak-STAT proteins or enhanced STAT5 signaling as reported previously. Basal levels of P-STAT3 were inversely correlated with IFN-alpha-induced P-STAT1 in cell lines (P = 0.013). IFN-alpha-induced formation of P-STAT1 was also variable in melanoma cells derived from patient tumors; however, no relationship between P-STAT3 and IFN-alpha-induced P-STAT1 was evident. Because IFN-alpha acts on both tumor and immune cells, we examined the ability of IFN-alpha to induce P-STAT1 in patient-derived melanoma cells and PBMCs. IFN-alpha induced significantly lower levels of P-STAT1 in melanoma cells compared with matched PBMCs (P = 0.046). Melanoma cells and human melanocytes required 10-fold higher IFN-alpha doses to exert P-STAT1 levels comparable with PBMCs.
Melanoma cells are variable in their IFN-alpha responsiveness, and cells of the melanocytic lineage exhibit a lower capacity for IFN-alpha-induced Jak-STAT signaling compared with immune cells.
向黑色素瘤患者施用α干扰素,其内源性产生对于免疫介导的肿瘤识别至关重要。我们假设信号转导子和转录激活子(STAT)1激活能力降低使黑色素瘤细胞能够逃避α干扰素的直接作用。
通过流式细胞术检测α干扰素刺激的人黑色素瘤细胞系、源自患者肿瘤的黑色素瘤细胞以及外周血单个核细胞(PBMC)中酪氨酸(701)磷酸化的STAT1(P-STAT1)。通过流式细胞术、免疫印迹或免疫组织化学评估其他Janus激活激酶(Jak)-STAT中间体(STAT1、STAT2、Jak1、酪氨酸激酶2、α干扰素受体、STAT3和STAT5)的表达。
在α干扰素处理后的人黑色素瘤细胞系中观察到P-STAT1存在显著差异(P < 0.05),且α干扰素诱导的P-STAT1与α干扰素的抗增殖作用相关(P = 0.042)。如先前报道,P-STAT1形成减少并非由Jak-STAT蛋白缺失或STAT5信号增强所致。细胞系中P-STAT3的基础水平与α干扰素诱导的P-STAT1呈负相关(P = 0.013)。在源自患者肿瘤的黑色素瘤细胞中,α干扰素诱导的P-STAT1形成也存在差异;然而,P-STAT3与α干扰素诱导的P-STAT1之间无明显关系。由于α干扰素对肿瘤细胞和免疫细胞均有作用,我们检测了α干扰素在源自患者的黑色素瘤细胞和PBMC中诱导P-STAT1的能力。与匹配的PBMC相比,α干扰素在黑色素瘤细胞中诱导的P-STAT1水平显著更低(P = 0.046)。黑色素瘤细胞和人黑素细胞需要比PBMC高10倍的α干扰素剂量才能产生相当水平的P-STAT1。
黑色素瘤细胞对α干扰素的反应性存在差异,与免疫细胞相比,黑素细胞系细胞诱导Jak-STAT信号的能力较低。